Table 1

Baseline patient characteristics

CharacteristicATG/GCSF
(n = 29)ATG only
(n = 29)Placebo
(n = 31)
Age (years)
 Mean ± SD17.2 ± 5.018.1 ± 6.916.9 ± 4.6
 Median16.415.515.0
 Range12.0–32.812.4–42.512.2–29.3
Male sex16 (55.2)17 (58.6)17 (54.8)
Race
 White28 (96.6)29 (100.0)29 (93.5)
 Black1 (3.4)0 (0.0)2 (6.5)
Ethnicity
 Not Hispanic and not Latino28 (96.6)27 (93.1)30 (96.8)
Autoantibody positive
 GAD-65H23 (79.3)23 (79.3)23 (74.2)
 IA-2H25 (86.2)23 (79.3)25 (80.6)
 ICA*26 (92.9)25 (86.2)22 (71.0)
 ZnT821 (72.4)21 (72.4)22 (71.0)
Number of autoantibodies positive*
 10 (0.0)3 (10.3)1 (3.2)
 23 (10.3)2 (6.9)3 (9.7)
 32 (6.9)1 (3.4)5 (16.1)
 411 (37.9)11 (37.9)13 (41.9)
 513 (44.8)12 (41.4)9 (29.0)
Days from diagnosis to randomization
 Median838184
 Range49–9747–10052–99
Weight (kg)
 Median62.366.462.0
 Range39.8–89.139.6–92.433.8–118
BMI (kg/m2)
 Median21.422.621.8
 Range16.6–27.715.2–32.814.3–34.3
AUC for C-peptide (nmol/L)
 Mean ± SD0.793 ± 0.3210.878 ± 0.4740.966 ± 0.503
 Median0.7010.7570.932
 Range0.338–1.780.211–2.150.144–2.08
HbA1c
 Median
  %7.37.47.2
  mmol/mol565755
 Range
  %5.3–12.34.7–9.05.5–11.2
  mmol/mol34–11128–7535–99
Total daily insulin dose at baseline* (units/kg)
 Median0.3390.3150.306
 Range0–1.060–0.9630–0.921
  • Data are n (%) unless otherwise indicated.

  • *Missing data: one patient was missing ICA status (had all four other autoantibodies positive), and three patients were missing baseline insulin dose.